New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 16, 2012
07:47 EDTDVAXDynavax a compelling buy at current levels, says Jefferies
Jefferies views Dynavax as a risky but compelling buy at current levels following the negative FDA panel vote on the company's hepatitis B vaccine. The firm lowered its price target for shares to $5 from $5 and keeps a Buy rating on the stock.
News For DVAX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 10, 2014
17:15 EDTDVAXDynavax files $200M mixed securities shelf
06:07 EDTDVAXDynavax announces DSMB recommendation to continue HEPLISAV-B Phase 3 study
Subscribe for More Information
November 7, 2014
17:06 EDTDVAXDynavax announces one-for-ten reverse stock split
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use